A Phase 3 trial published in the New England Journal of Medicine shows baxdrostat, a selective aldosterone synthase inhibitor developed by AstraZeneca, significantly lowers blood pressure in patients with resistant and uncontrolled hypertension. The BaxHTN trial enrolled 796 patients across 214 clinics worldwide, with 73% suffering from resistant hypertension despite taking three or more medications.
After 12 weeks, patients on the 2 mg dose saw placebo-adjusted systolic blood pressure drop by 9.8 mmHg, with 40% reaching the target level below 130 mmHg — compared to just 18.7% on placebo. Ambulatory monitoring showed even larger reductions of 16.9 mmHg over 24 hours. Safety was generally favorable, with confirmed high potassium levels occurring in about 1% of patients.
Professor Bryan Williams from University College London, who presented the results, called baxdrostat "one of the first therapies" to selectively block aldosterone production. A meta-analysis of three trials presented at the American College of Cardiology 2026 conference confirmed the consistent blood pressure-lowering effect. The FDA has already accepted AstraZeneca's application for priority review.
